Year: 2023

Incyte Becomes 26th Drugmaker to Place Contract Pharmacy Restrictions

September 21, 2023 Rich Daly, Editor in Chief Views

Incyte will no longer allow 340B hospitals to have direct delivery of Opzelura products purchased at the 340B discount price to contract pharmacies.

Drug manufacturer Incyte Corp. this week announced it will become the 26th drug manufacturer to restrict access to 340B pricing when [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

One Quarter of HRSA Provider Audits Closed with No Adverse Findings

September 21, 2023 Rich Daly, Editor in Chief Views

Dept. of Health and Human Services sign and building

There were no adverse findings in nearly one quarter of provider audits conducted by HRSA, an agency within HHS.

Nearly one-quarter of the 200 provider audits planned for this year were closed by regulators with no adverse findings, they [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

GOP Scrutinizes Medicare Price Negotiations in House Subcommittee Hearing

September 21, 2023 William Newton, Associate Editor/Senior Writer Views

A 340B hearing next week called by Rep. Cathy McMorris Rodgers (R-Wash.), chair of the E&C Committee, will include as witnesses a policy researcher critical of 340B and a community health center leader.

Republicans and Democrats battled over Medicare price negotiation provisions under the Inflation Reduction Act (IRA) during a contentious Sept. 20 [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B INDUSTRY LEADER SPOTLIGHT

Jason Reddish, Principal, Powers Law Firm

September 21, 2023 Diane Slafsky Views

Jason Reddish

Q: Where did you grow up?

I grew up in Salisbury, Maryland, a town of about 25,000 on the Delmarva Peninsula.

Q: Where did you go to college/graduate school?

I went to the University of Maryland, where I studied physiology/neurobiology, graduating in 2001. I attended law school at Tulane in New Orleans, graduating in 2005.

Q: What

…

Providers Split on 340B Medicaid Provisions in Major House Healthcare Package

September 19, 2023 William Newton, Associate Editor/Senior Writer Views

Joe Dunn, senior vice president of public policy and research at NACHC, said his organization supported the Lower Costs, More Transparency Act.

Provider groups diverged over 340B Medicaid managed care provisions in a sweeping healthcare package on which the House of Representatives [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

AHF Files Appeal Over Its Claim That Apexus Did Not Obtain Sub-Ceiling Discounts

September 19, 2023 Rich Daly, Editor in Chief Views

AHF appealed a ruling to dismiss by U.S. District Judge Percy Anderson over AHF's claim that Apexus did not obtain sub-ceiling discounts..

The AIDS Healthcare Foundation (AHF) recently filed an appeal to an April district court dismissal of its case against Apexus, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Health Center Challenging 340B Patient Definition Responds to HRSA’s and Drug Companies’ Court Arguments

September 19, 2023 Tom Mirga, Editor at Large Views

Genesis Health Care successfully challenged HRSA's 340B patient definition in the U.S. District Court for the District of South Carolina.

There is no evidence to support federal allegations that a South Carolina community health center illegally diverts 340B-purchased drugs to [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Uncertain Outlook for GOP Drug Shortages Bill with 340B Provisions

September 19, 2023 William Newton, Associate Editor/Senior Writer Views

Rep. Anna Eshoo, ranking member of the E&C Health Subcommittee, was one of multiple Democrats opposed to a Republican drug shortages bill.

The future of a Republican drug shortages bill with 340B provisions remains unclear after it was examined in a contentious [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Novo Nordisk Providing 340B Refunds on Blockbuster Drug Ozempic

September 19, 2023 Tom Mirga, Editor at Large Views

Drugmaker Novo Nordisk is issuing 340B refunds for certain purchases of its blockbuster diabetes medication Ozempic.

Novo Nordisk will issue refunds to 340B covered entities for some purchases this year of its blockbuster injectable diabetes medication [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

AHIP Objects to Hospital Efforts to Target Medicare Advantage 340B ‘Windfall’

September 19, 2023 Rich Daly, Editor in Chief Views

Matthew Eyles, president and CEO of AHIP, objected to hospital-sought rules that target the Medicaid Advantage 340B "windfall."

The largest health insurer advocacy organization urged federal regulators to reject hospital-sought rules to limit the ability of Medicare Advantage [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

340B INDUSTRY LEADER SPOTLIGHT

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Site Footer Live